Cardiovascular disorders

The TIMI Risk Score for Atherothrombosis in Diabetes categorises risk of myocardial infarction or stroke in people with type 2 diabetes.

Real-world study data show that non-fasting remnant cholesterol levels are associated with a significantly increased risk for CVD in people without diabetes, with a similar, but nonsignificant, trend observed in those with diabetes.

A case-crossover study supports a link between use of non-steroidal anti-inflammatory drugs and development of heart failure in people with type 2 diabetes.

A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

Click through to read more on this announcement

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.

Having type 2 diabetes increases a person’s risk for a cancer being already metastatic at the point of diagnosis, shows an EPIC analysis.

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.